Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs

Autor: Dimitrios A, Pappas, Michele M, Hooper, Joel M, Kremer, George, Reed, Ying, Shan, Deborah, Wenkert, Jeffrey D, Greenberg, Jeffrey R, Curtis

Publikováno v: Arthritis careresearch. 67(12)

To identify the rheumatoid arthritis (RA) characteristics associated with increased herpes zoster (HZ) risk in the Corrona registry RA patients, and to evaluate the risk in initiators of tumor necrosis factor inhibitors (TNFi) or non-TNFi biologic ag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f8dc6f2fd21350d6d49fd797f0131a3e
https://pubmed.ncbi.nlm.nih.gov/26018115

Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.

Autor: Jacobson CA; Dana-Farber Cancer Institute, Boston, Massachusetts., Locke FL; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Ma L; Kite Pharma, a Gilead Company, Santa Monica, California., Asubonteng J; Kite Pharma, a Gilead Company, Santa Monica, California., Hu ZH; Kite Pharma, a Gilead Company, Santa Monica, California., Siddiqi T; City of Hope National Medical Center, Duarte, California., Ahmed S; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ghobadi A; Washington University School of Medicine, St. Louis, Missouri., Miklos DB; Stanford University School of Medicine, Stanford, California., Lin Y; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Perales MA; Memorial Sloan Kettering Cancer Center, New York, New York., Lunning MA; University of Nebraska Medical Center, Omaha, Nebraska., Herr MM; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Hill BT; Cleveland Clinic Foundation, Cleveland, Ohio., Ganguly S; Houston Methodist Hospital and Cancer Center, Houston, Texas., Dong H; Kite Pharma, a Gilead Company, Santa Monica, California., Nikiforow S; Dana-Farber Cancer Institute, Boston, Massachusetts., Hooper M; Kite Pharma, a Gilead Company, Santa Monica, California., Kawashima J; Kite Pharma, a Gilead Company, Santa Monica, California., Xu H; Kite Pharma, a Gilead Company, Santa Monica, California., Pasquini MC; Medical College of Wisconsin/Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin. Electronic address: mpasquini@mcw.edu.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2022 Sep; Vol. 28 (9), pp. 581.e1-581.e8. Date of Electronic Publication: 2022 May 21.

OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.

Autor: Kimball AB; Massachusetts General Hospital, Boston, Massachusetts. Electronic address: harvardskinstudies@partners.org., Rothman KJ; RTI Health Solutions, RTI International, Research Triangle Park, North Carolina., Kricorian G; Amgen Inc, Thousand Oaks, California., Pariser D; Eastern Virginia Medical School and Virginia Clinical Research Inc, Norfolk, Virginia., Yamauchi PS; Dermatology Institute and Skin Care Center, Santa Monica, California., Menter A; Baylor Research Institute, Dallas, Texas., Teller CF; Bellaire Dermatology Associates, Bellaire, Texas., Aras G; Amgen Inc, Thousand Oaks, California., Accortt NA; Amgen Inc, Thousand Oaks, California., Hooper M; Amgen Inc, Thousand Oaks, California., Rice KC; Amgen Inc, Thousand Oaks, California., Gelfand JM; University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2015 Jan; Vol. 72 (1), pp. 115-22. Date of Electronic Publication: 2014 Sep 26.

A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.

Autor: Lebwohl MG; Mount Sinai Medical Center, New York, New York, USA., Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2013 Sep; Vol. 69 (3), pp. 385-92. Date of Electronic Publication: 2013 May 01.

OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis.

Autor: Kimball AB; Massachusetts General Hospital, Boston, Massachusetts 02114, USA. harvardskinstudies@partners.org, Pariser D, Yamauchi PS, Menter A, Teller CF, Shi Y, Yong M, Creamer K, Hooper M, Aras G, Kricorian G, Gelfand JM

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2013 May; Vol. 68 (5), pp. 756-64. Date of Electronic Publication: 2013 Jan 26.